503A vs 503B pharmacy: what the difference means for compounded GLP-1 in 2026
Most patients holding a vial of compounded tirzepatide cannot say which type of pharmacy made it. A 2025 national poll found 42% of US adults are familiar with pharmacy compounding, yet nearly one-third still lack a basic understanding of what it involves. The category your pharmacy operates under is not regulatory trivia. As of March 2025, 503B outsourcing facilities can no longer compound tirzepatide at all, so 503a vs 503b pharmacy decides whether your prescription is even legal in 2026, who inspects the facility that filled it, and what testing it underwent.
Patients who want a step-by-step playbook can jump straight to how to verify your pharmacy. The rest of this page explains the framework that lookup is built on: a 30-second comparison table, a deep dive on each tier, and a practical how-to-tell.
Why two compounding categories exist (and the 30-second comparison table)
In 2012, the New England Compounding Center shipped fungus-contaminated methylprednisolone acetate from one Massachusetts facility to 75 clinics across 23 states. Sixty-four patients died, 798 were sickened. NECC was licensed as 503A but functioning as a manufacturer, and the pre-2013 jurisdictional gap left FDA deferring to states. Congress responded with the Drug Quality and Security Act (DQSA) of 2013, keeping patient-specific compounding under Section 503A and creating Section 503B for facilities at manufacturer scale, with mandatory FDA registration and current Good Manufacturing Practice (cGMP) compliance.
| Attribute | 503A pharmacy | 503B outsourcing facility | NDA-approved (Mounjaro / Zepbound) |
|---|---|---|---|
| Statute | 21 USC 353a | 21 USC 353b | NDA approval, FDCA |
| Prescription requirement | Patient-specific Rx required | Not required (bulk allowed) | Patient-specific Rx required |
| Scale | Individual prescriptions | Manufacturer-scale batches | Commercial production |
| Oversight | State board and DEA | FDA registration, risk-based inspection | FDA, full lifecycle |
| USP / cGMP | USP <795>, <797>, <800>; no cGMP | USP plus full cGMP (21 CFR 210/211) | Full cGMP |
| FDA inspection | Not routine | Risk-based, heavy backlog | Pre-approval and ongoing |
| Tirzepatide in 2026 | Legal only with documented clinical difference | Prohibited since March 19, 2025 | Commercially available |
Scott Brunner of the Alliance for Pharmacy Compounding frames the line as a purpose distinction: 503A serves individual customization, 503B serves supply scale. The next three sections walk each tier.
1. 503A: the patient-specific compounding tier
Most patients have already used a 503A pharmacy without realizing it. The local compounding pharmacy down the street is one. So is most of the telehealth GLP-1 supply chain in 2026.
503A is governed by 21 USC 353a, originally created by FDAMA 1997 and tightened by DQSA 2013. A 503A pharmacy registers with its state board of pharmacy and the DEA, not with FDA. The agency does not interact with the vast majority of 503A pharmacists.
Quality standards come from the United States Pharmacopeia. USP <795> covers non-sterile compounding. USP <797> covers sterile compounding, the chapter that governs every compounded tirzepatide injectable. USP <800> covers hazardous drug handling. A 503A pharmacy is not required to follow 21 CFR Parts 210 and 211, the federal cGMP rules that bind drug manufacturers and 503B facilities. That is the core 503A and 503B difference behind every other line on the table.
"Patient-specific" is the defining condition. Each compound must be prepared for an identified individual patient based on a valid prescription order, per 21 USC 353a(a)(2). A limited anticipatory pathway lets pharmacies pre-mix small quantities, but bulk production for office use is off-limits. Telehealth prescriptions do satisfy the patient-specific requirement when issued by a licensed prescriber for a named patient.
Best for: individualized formulations a commercial product cannot match.
2. 503B outsourcing facilities: the manufacturer-grade compounding tier
Of the 48 503B outsourcing facilities newly registered with FDA since June 2021, 39 (81%) had never been inspected by the agency as of mid-2025. Of the 55 facilities that had been inspected, 96% received Form 483 citations. Read every cGMP claim that follows with that calibration.
503B was created by DQSA 2013 and is governed by 21 USC 353b. Every 503B facility must register with FDA and appears on the public Registered Outsourcing Facilities list at fda.gov, updated weekly. So what is 503B compounding? Compounding done at manufacturer scale under federal pharmaceutical manufacturing standards.
cGMP under 21 CFR Parts 210 and 211 adds layers USP alone does not require: process validation, lot-specific testing for potency, sterility, and endotoxins before release, an independent quality department, and environmental monitoring at every production shift for ISO 5 cleanrooms (versus every six months for 503A). Beyond-use dating rests on validated stability studies.
A 503B outsourcing facility can produce large batches without patient-specific prescriptions, distribute interstate, supply healthcare facilities for office-use stocking, and assign extended beyond-use dates. Those capabilities made 503B the natural compounded GLP-1 pipeline during the shortage years.
Registration is not approval. The Partnership for Safe Medicines warned the current inspection lag mirrors the pre-2013 conditions that produced NECC. Verdict: 503B is built for institutional supply at scale, and the inspection record is the load-bearing variable.
3. The third tier most readers miss: NDA-approved Mounjaro and Zepbound
Branded tirzepatide is the cleanest regulatory category in the comparison, which simplifies everything that follows.
Mounjaro (tirzepatide for type 2 diabetes) and Zepbound (tirzepatide for chronic weight management and moderate-to-severe obstructive sleep apnea) are both manufactured by Eli Lilly under a New Drug Application. NDA approval means full FDA review of safety, efficacy, and manufacturing before market, plus ongoing cGMP under 21 CFR 210/211. The molecule is identical between brands; only the indication differs.
Because Mounjaro and Zepbound are commercially available, any compounded tirzepatide that does not produce a clinically significant difference for an individual patient is now treated as "essentially a copy" under Section 503A and prohibited.
Pricing context explains the cost-driven default. List price for Zepbound is roughly $1,086 per 28-day supply; Mounjaro about $1,080. Under a 2026 government pricing agreement, Medicare and Medicaid pay $245. TrumpRx averages $346 per month. Compounded historically ran $250 to $400 per month, a gap that has since narrowed and no longer counts as a permitted basis for compounding.
4. Why 503B was the GLP-1 sweet spot, and why that door closed in March 2025
How did a category filling thousands of GLP-1 prescriptions in 2024 stop overnight?
503B fit GLP-1 demand almost perfectly during the shortage years. Tirzepatide and semaglutide were on the FDA shortage list, which gave 503B operators statutory cover under Section 503B(a)(2) to compound bulk substances even when a commercial version existed. Compounded GLP-1 ranked among the top three compounded therapies by volume in 2025-2026 surveys. Bulk production, interstate shipping, and a sub-$400 monthly price made 503B the dominant telehealth pipeline.
The closing timeline is short. FDA declared the tirzepatide shortage resolved December 19, 2024. Enforcement discretion for 503A ended February 18, 2025; for 503B it ended March 19, 2025. The Outsourcing Facilities Association sought a preliminary injunction. The US District Court for the Northern District of Texas denied the motion on March 5, 2025, then upheld FDA's shortage determination on May 7, 2025. For the full chronology, the March 2025 shutdown explains why 503B is gone.
This is not a pause. Tirzepatide is not on the 503B Bulks List. On April 30, 2026, FDA proposed formally excluding semaglutide, tirzepatide, and liraglutide from the Bulks List, foreclosing any future shortage-based reopening. For verifying a 503A pharmacy, you can look up your pharmacy's state license, and for accreditation context see the dedicated bridge.
The market did not disappear. It migrated to 503A under narrower rules.
5. What 503A compounded tirzepatide actually looks like in 2026
Patients who lost affordable supply in early 2025 are now filling tirzepatide-plus-vitamin compounds through telehealth platforms, often without knowing what changed.
A 503A pharmacy may still legally compound tirzepatide under narrow circumstances: a documented medical reason the commercial product does not meet the patient's clinical needs, or a formulation with a clinically significant difference such as tirzepatide combined with niacinamide, B6, B12, or glycine. The prescriber records the clinical necessity on the prescription itself.
Empower Pharmacy's tirzepatide/niacinamide injection is the cleanest worked example. Three formulations: 17/2 mg/mL in 4 mL, 8/2 mg/mL in 2.5 mL, and 17/2 mg/mL in 2 mL. A patient-specific Rx is required. Empower also operates a 503B facility but routes this product exclusively through 503A because no other route is legal in 2026.
Three safety questions deserve weight. First, batch-to-batch variability is structural: 503A beyond-use dates rest on literature, not validated stability testing. Second, on March 12, 2026 Eli Lilly issued an open letter flagging a novel impurity in tirzepatide compounded with B12 whose effects in humans are unknown. Third, Georgetown Law scholar Shweta Kumar has argued that adding vitamins solely to evade the "essentially a copy" rule violates FDA guidance.
Quick comparison: 2026 503A is a narrow, prescriber-documented pathway. 2024 503B was a mass market. Same molecule, different rules.
6. How to tell which category fills your prescription
This check takes 60 seconds.
- Search the FDA Registered Outsourcing Facilities list at fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities. If your pharmacy is on it, the facility is a 503B.
- If your pharmacy is not on the list, it is a 503A regulated by your state board of pharmacy, not FDA.
- Read the label. A multi-dose vial without a patient-specific name most often came from a 503B. A vial with your name on it came from a 503A patient-specific dispense.
- Read the formulation. Tirzepatide combined with niacinamide, B6, B12, or glycine is by definition a 503A formulation in 2026, since 503B cannot legally compound tirzepatide.
- Watch the price. Sub-$400 monthly compounded tirzepatide in 2024 was almost always 503B-sourced. Any sub-$400 price in 2026 should prompt verification that the source is genuinely 503A with documented clinical justification.
- Ask the pharmacy directly. They are required to operate under one designation and should answer in one sentence.
If "is my pharmacy 503A or 503B" still feels uncertain, call the dispensing pharmacist on duty.
Bottom line: 503A vs 503B for compounded GLP-1 in 2026
503A and 503B are not a quality hierarchy. They are a purpose distinction, as Scott Brunner of the Alliance for Pharmacy Compounding has put it, and that distinction now decides what is legal for compounded tirzepatide.
- NDA-approved Mounjaro or Zepbound is the regulatory baseline: full FDA review, ongoing cGMP, with the 2026 Medicare/Medicaid agreement at $245 and TrumpRx averaging $346 narrowing the historical cost gap.
- 503B outsourcing facilities operate under cGMP and FDA registration, but cannot legally compound tirzepatide as of March 19, 2025, with permanent Bulks List exclusion proposed April 30, 2026.
- 503A pharmacies remain the only legal compounding pathway for tirzepatide in 2026, and only under a documented clinically significant difference. Both the specific pharmacy you choose and the specific formulation you receive now matter more than the tier label alone, since 503A oversight varies meaningfully by state board.
Patients who want a vetted starting point can review verified-safe 503A providers.
Frequently asked questions
Is my pharmacy 503A or 503B?
Search the FDA's Registered Outsourcing Facilities list at fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities. If your pharmacy appears, it is a 503B. If not, it is a 503A regulated by your state board. Ask the dispensing pharmacist to confirm.
Can I still get compounded tirzepatide in 2026?
Only through a 503A pharmacy under narrow conditions. 503B tirzepatide compounding ended March 19, 2025. A 503A pharmacy can compound tirzepatide if your prescriber documents a clinical reason the commercial product does not meet your needs, or for a formulation with a clinically significant difference such as tirzepatide plus niacinamide. Cost alone is not valid.
Is a 503B pharmacy safer than a 503A pharmacy?
On paper, 503B has stricter standards: cGMP, lot-specific release testing, independent quality assurance. In practice, mid-2025 data showed 81% of newly registered 503Bs had never been FDA-inspected and 96% of those inspected received Form 483 citations. PCAB or ACHC accreditation is the practical 503A quality differentiator.
Does the FDA inspect 503A pharmacies?
Not on a routine schedule. Primary oversight of 503A sits with the state board of pharmacy and the DEA. FDA can intervene in specific cases, including interstate distribution complaints or NECC-style misuse where a 503A operates as a de facto manufacturer. Routine cGMP inspection authority lives with 503B and NDA-approved manufacturers.
Is compounded tirzepatide as good as Mounjaro or Zepbound?
Compounded preparations from any source are not FDA-approved; no agency review of safety, efficacy, or manufacturing quality occurs before dispensing. 503A-compounded GLP-1 carries documented batch-to-batch variability, and FDA has logged more than 320 adverse-event reports tied to compounded tirzepatide. Branded products remain the reference.